October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 28, 2025

Insurance Shake-Up: Who Loses Out?

Families nationwide face rising health insurance costs as Affordable Care Act subsidies near expiration, with premiums and deductibles projected to increase amid congressional inaction.

KFF Health News

October 27, 2025

State to End Vaccine Mandates — What Then?

After decades of required shots, Florida plans to make school immunizations optional — and experts stay quiet.

KFF Health News

October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant

October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Obinutuzumab Wins FDA Nod for Lupus Nephritis

Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.

Conexiant

October 20, 2025

Tezepelumab FDA Approval Expands Use to Nasal Polyps

AstraZeneca and Amgen’s anti-thymic stromal lymphopoietin biologic reduces nasal polyp burden and corticosteroid use in the phase 3 WAYPOINT trial.

Conexiant